KMDA - Kamada Ltd.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
5.70
0.00 (0.00%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close5.70
Open5.75
Bid0.00 x 2900
Ask0.00 x 3200
Day's Range5.60 - 6.10
52 Week Range3.75 - 6.10
Volume47,513
Avg. Volume17,823
Market Cap234.228M
Beta1.44
PE Ratio (TTM)18.63
EPS (TTM)0.31
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.33
Trade prices are not sourced from all markets
  • CVS will offer home delivery of prescriptions
    Yahoo Finance Videolast month

    CVS will offer home delivery of prescriptions

    In an effort to stave off Amazon, CVS will roll-out nationwide delivery of prescription medication. Yahoo Finance's Seana Smith, Ethan Wolff-Mann, David Pogue and Rick Newman discuss.

  • Biotech and energy top list for best paying jobs
    Yahoo Finance Video2 months ago

    Biotech and energy top list for best paying jobs

    Engineers in both the energy and biotech sectors are among top earners, surpassing Wall Street. Yahoo Finance's Seana Smith, Jennifer Rogers and Pras Subramanian discuss.

  • GlobeNewswire12 days ago

    Kamada Receives Positive Scientific Advice from European Medicines Agency on a New Phase 3 Study Design for Inhaled AAT

    The Company requested scientific advice (protocol assistance) from the CHMP following the results of the previous Phase 2/3 (EU) and Phase 2 (US) studies conducted by the Company with respect to a proposed subsequent Phase 3 study design. The CHMP notified the Company that it concurs with the overall design of the proposed study, including its objectives, patient population, proposed endpoints and their clinical importance, and the safety monitoring plan.

  • Is Kamada (KMDA) Outperforming Other Medical Stocks This Year?
    Zacks24 days ago

    Is Kamada (KMDA) Outperforming Other Medical Stocks This Year?

    Is (KMDA) Outperforming Other Medical Stocks This Year?

  • 4 Undervalued MedTech Stocks to Consider Amid Volatility
    InvestorPlacelast month

    4 Undervalued MedTech Stocks to Consider Amid Volatility

    The U.S. medical device industry has exhibited strong and sustainable growth of late due to an aging population and increasing incidences of chronic and lifestyle diseases. Elimination of the tax will result in huge savings for the medical device players, in turn compelling them to focus on innovation. Per consulting specialist Emergo, the U.S. medical device industry was valued at $147.7 billion in 2016 and is projected to grow significantly through 2019 to $173 billion.

  • 5 Biotech Stocks Under $10 Worthy of Investors' Attention
    Zackslast month

    5 Biotech Stocks Under $10 Worthy of Investors' Attention

    Small biotech stocks are good bets with lower market cap as well as share price.

  • GlobeNewswire2 months ago

    Results of Kamada’s Phase 2 Trial of Alpha-1 Antitrypsin in Newly Diagnosed Type-1 Diabetes Patients to be Presented at the Upcoming American Diabetes Association’s 78th Scientific Sessions

    “We are excited to present the data from our Phase 2 trial of AAT in newly diagnosed T1D patients at such a prestigious medical conference,” said Amir London, Kamada’s Chief Executive Officer.  “Based on the results generated to date, and feedback received from the medical community, we believe that further studies in a larger population are warranted.

  • Associated Press2 months ago

    Kamada: 1Q Earnings Snapshot

    On a per-share basis, the Ness Ziona, Israel-based company said it had profit of 3 cents. The biopharmaceutical posted revenue of $17.4 million in the period. Kamada expects full-year revenue in the range ...

  • GlobeNewswire2 months ago

    Kamada Reports Financial Results for First Quarter of 2018

    Reaffirming Guidance of $116 to $120 Million in Total Revenues for 2018 U.S. Launch of KEDRAB ® Represents Significant Company Milestone REHOVOT, Israel, May 15, 2018-- Kamada Ltd., a plasma-derived protein ...

  • ACCESSWIRE2 months ago

    Kamada Ltd to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 15, 2018 / Kamada Ltd (NASDAQ: KMDA ) will be discussing their earnings results in their Q1 Earnings Call to be held on May 15, 2018 at 8:30 AM Eastern Time. To listen to ...

  • GlobeNewswire2 months ago

    Kamada to Announce First Quarter 2018 Financial Results and Host Conference Call on May 15

    Kamada Ltd. (KMDA) (KMDA.TA), a plasma-derived protein therapeutics company, today announced that it will release financial results for the quarter ended March 31, 2018, prior to the open of the U.S. financial markets on Tuesday, May 15, 2018. Kamada management will host an investment community conference call on Tuesday, May 15 at 8:30am Eastern Time to discuss these results and answer questions. Shareholders and other interested parties may participate in the conference call by dialing 866-548-4713 (from within the U.S.), 1 80 924 3003 (from Israel), or 323-794-2093 (International) and entering the conference identification number: 2302061.

  • Business Wire2 months ago

    Kedrion Biopharma and Kamada Announce KEDRAB® (Rabies Immune Globulin ) Now Shipping; Distribution Timed to Meet Spring/Summer Demand for Product

    Kedrion Biopharma and Kamada Ltd. (KMDA) (KMDA.TA), two leading human-derived protein therapeutics companies, announced today that KEDRAB® [Rabies Immune Globulin (Human)] has been launched in the U.S. and initial shipments are now reaching healthcare practitioners across the country. Deliveries have been timed to meet growing demand for this product as the height of the 2018 spring/summer rabies season approaches. KEDRAB, a human rabies immune globulin (HRIG), received U.S. Food and Drug Administration (FDA) approval for passive, transient post-exposure prophylaxis of rabies infection, when given immediately after contact with a rabid or possibly rabid animal and concurrent with the rabies vaccine. Prior to FDA approval of KEDRAB, U.S. healthcare professionals had only two HRIG therapy options from which to choose to prevent the onset of rabies in someone who may have been exposed to the deadly virus. KEDRAB, the newest entry into the $100 million plus U.S. rabies market, represents another safe, effective treatment choice for healthcare professionals seeking an alternative to currently available HRIGs.

  • GlobeNewswire2 months ago

    Kedrion Biopharma and Kamada Announce KEDRAB® (Rabies Immune Globulin ) Now Shipping; Distribution Timed to Meet Spring/Summer Demand for Product

    Kedrion Biopharma and Kamada Ltd. (KMDA) (KMDA.TA), two leading human-derived protein therapeutics companies, announced today that KEDRAB® [Rabies Immune Globulin (Human)] has been launched in the U.S. and initial shipments are now reaching healthcare practitioners across the country. Deliveries have been timed to meet growing demand for this product as the height of the 2018 spring/summer rabies season approaches. KEDRAB, a human rabies immune globulin (HRIG), received U.S. Food and Drug Administration (FDA) approval for passive, transient post-exposure prophylaxis of rabies infection, when given immediately after contact with a rabid or possibly rabid animal and concurrent with the rabies vaccine. Prior to FDA approval of KEDRAB, U.S. healthcare professionals had only two HRIG therapy options from which to choose to prevent the onset of rabies in someone who may have been exposed to the deadly virus. KEDRAB, the newest entry into the $100 million plus U.S. rabies market, represents another safe, effective treatment choice for healthcare professionals seeking an alternative to currently available HRIGs.

  • Israel-based Medical Cannabis Solutions Provider, Kanabo Research, has Signed an Agreement With Constance Therapeutics From the US
    PR Newswire3 months ago

    Israel-based Medical Cannabis Solutions Provider, Kanabo Research, has Signed an Agreement With Constance Therapeutics From the US

    TEL AVIV, Israel, April 25, 2018 /PRNewswire/ -- Israeli startup Kanabo Research, which develops clinical solutions for extraction and vaporization of medical cannabis, announces it is entering an agreement with Constance Therapeutics, a US-based medical cannabis extraction company. According to the agreement, both companies will operate in the EU to establish a cannabis cultivation farm as well as manufacturing capabilities of cannabis active compounds – THC and CBD – to be used in an array of medical treatments and chronic ailments such as insomnia, PTSD and chronic pain.

  • Market Exclusive3 months ago

    Here’s What Just Happened With Prothena And Kamada

    Prothena Corporation plc (NASDAQ:PRTA) is attracting a substantial amount of attention in the biotechnology space early this week on the back of news that the company has decided to discontinue one of its lead development programs. This is a major setback and, as might be expected, Prothena shares have taken a hit in line with […] The post Here’s What Just Happened With Prothena And Kamada appeared first on Market Exclusive.

  • MarketWatch3 months ago

    Kamada shares drop on FDA's continued concerns about therapy's safety, trial delay

    Kamada Ltd. shares dropped 4.4% in premarket trade Monday on news that the company has not been able to resolve the Food and Drug Administration's concerns about the safety of its therapy, which will delay a phase 3 clinical trial that Kamada had planned for the second half of the year. It's also possible the trial may not happen, Kamada suggested. The product, Inhaled Alpha-1 Antitrypsin, is intended to treat Alpha-1 Antitrypsin Deficiency, a genetic disorder that can lead to lung and liver disease.

  • GlobeNewswire3 months ago

    Kamada Received Feedback from FDA on Proposed Phase 3 Protocol for Inhaled Alpha-1-Antitrypsin for Treatment of Alpha-1 Antitrypsin Deficiency Disease

    REHOVOT, Israel, April 23, 2018-- Kamada Ltd., a plasma-derived protein therapeutics company, today announced that the Company recently received feedback from the U.S. Food and Drug Administration regarding ...

  • Associated Press5 months ago

    Kamada posts 4Q profit

    On a per-share basis, the Ness Ziona, Israel-based company said it had net income of 16 cents. The biopharmaceutical posted revenue of $35.7 million in the period. For the year, the company reported net ...

  • Capital Cube8 months ago

    ETFs with exposure to Kamada Ltd. : December 1, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Kamada Ltd. Here are 5 ETFs with the largest exposure to KMDA-US. Comparing the performance and risk of Kamada Ltd. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Kamada Ltd. :KMDA-US: Earnings Analysis: Q3, 2017 By the Numbers : November 30, 2017
    Capital Cube8 months ago

    Kamada Ltd. :KMDA-US: Earnings Analysis: Q3, 2017 By the Numbers : November 30, 2017

    Categories: Yahoo FinanceGet free summary analysis Kamada Ltd. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Kamada Ltd. – Anthera Pharmaceuticals, Inc., Compugen Ltd. and Vertex Pharmaceuticals Incorporated (ANTH-US, CGEN-US and VRTX-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD ... Read more (Read more...)